<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName archivearticle3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Obes Metab</journal-id><journal-id journal-id-type="iso-abbrev">Diabetes Obes Metab</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1463-1326</journal-id><journal-id journal-id-type="publisher-id">DOM</journal-id><journal-title-group><journal-title>Diabetes, Obesity &amp; Metabolism</journal-title></journal-title-group><issn pub-type="ppub">1462-8902</issn><issn pub-type="epub">1463-1326</issn><publisher><publisher-name>Blackwell Publishing Ltd</publisher-name><publisher-loc>Oxford, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5947126</article-id><article-id pub-id-type="doi">10.1111/dom.13209</article-id><article-id pub-id-type="publisher-id">DOM13209</article-id><article-categories><subj-group subj-group-type="overline"><subject>Brief Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Brief Reports</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Dapagliflozin for prednisone‐induced hyperglycaemia in acute exacerbation of chronic obstructive pulmonary disease </plain></SENT>
</text></SecTag></article-title><alt-title alt-title-type="left-running-head">Gerards et al</alt-title></title-group><contrib-group><contrib id="dom13209-cr-0001" contrib-type="author" corresp="yes"><name><surname>Gerards</surname><given-names>Maaike C.</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1034-4141</contrib-id><address><email>m.c.gerards@amc.uva.nl</email></address><xref ref-type="aff" rid="dom13209-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="dom13209-cr-0002" contrib-type="author"><name><surname>Venema</surname><given-names>Gerdien E.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="dom13209-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="dom13209-cr-0003" contrib-type="author"><name><surname>Patberg</surname><given-names>Kornelis W.</given-names></name><degrees>MD PhD</degrees><xref ref-type="aff" rid="dom13209-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="dom13209-cr-0004" contrib-type="author"><name><surname>Kross</surname><given-names>Martijn</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="dom13209-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="dom13209-cr-0005" contrib-type="author"><name><surname>Potter van Loon</surname><given-names>Bert Jan</given-names></name><degrees>MD PhD</degrees><xref ref-type="aff" rid="dom13209-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="dom13209-cr-0006" contrib-type="author"><name><surname>Hageman</surname><given-names>Ilse M. G.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="dom13209-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="dom13209-cr-0007" contrib-type="author"><name><surname>Snijders</surname><given-names>Dominic</given-names></name><degrees>MD PhD</degrees><xref ref-type="aff" rid="dom13209-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="dom13209-cr-0008" contrib-type="author"><name><surname>Brandjes</surname><given-names>Dees P.M.</given-names></name><degrees>MD PhD</degrees><xref ref-type="aff" rid="dom13209-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="dom13209-cr-0009" contrib-type="author"><name><surname>Hoekstra</surname><given-names>Joost B. L.</given-names></name><degrees>MD PhD</degrees><xref ref-type="aff" rid="dom13209-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="dom13209-cr-0010" contrib-type="author"><name><surname>Vriesendorp</surname><given-names>Titia M.</given-names></name><degrees>MD PhD</degrees><xref ref-type="aff" rid="dom13209-aff-0007">
<sup>7</sup>
</xref></contrib><contrib id="dom13209-cr-0011" contrib-type="author"><name><surname>Gerdes</surname><given-names>Victor E. A.</given-names></name><degrees>MD PhD</degrees><xref ref-type="aff" rid="dom13209-aff-0001">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="dom13209-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Department of Internal Medicine</named-content>
<institution>MC Slotervaart</institution>
<named-content content-type="city">Amsterdam</named-content>
<country country="NL">The Netherlands</country>
</aff><aff id="dom13209-aff-0002" content-type="private-address">
<label><sup>2</sup></label>
<institution>Department of Pulmonology</institution>
<named-content content-type="city">Isala, Zwolle</named-content>
<country country="NL">The Netherlands</country>
</aff><aff id="dom13209-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Department of Pulmonology</named-content>
<institution>MC Slotervaart</institution>
<named-content content-type="city">Amsterdam</named-content>
<country country="NL">The Netherlands</country>
</aff><aff id="dom13209-aff-0004">
<label><sup>4</sup></label>
<named-content content-type="organisation-division">Department of Internal Medicine</named-content>
<institution>OLVG West</institution>
<named-content content-type="city">Amsterdam</named-content>
<country country="NL">The Netherlands</country>
</aff><aff id="dom13209-aff-0005">
<label><sup>5</sup></label>
<named-content content-type="organisation-division">Department of Pulmonology</named-content>
<institution>Spaarne Gasthuis</institution>
<named-content content-type="city">Hoofddorp</named-content>
<country country="NL">The Netherlands</country>
</aff><aff id="dom13209-aff-0006">
<label><sup>6</sup></label>
<named-content content-type="organisation-division">Academic Medical Centre</named-content>
<institution>Department of Internal Medicine</institution>
<named-content content-type="city">Amsterdam</named-content>
<country country="NL">The Netherlands</country>
</aff><aff id="dom13209-aff-0007" content-type="private-address">
<label><sup>7</sup></label>
<institution>Department of Internal Medicine</institution>
<named-content content-type="city">Isala, Zwolle</named-content>
<country country="NL">The Netherlands</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Maaike C. Gerards MD, Medical Centre Slotervaart, Department of Internal Medicine, Louwesweg 6, 1066 EC, Amsterdam, The Netherlands<break/>
Email: <email>m.c.gerards@amc.uva.nl</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>06</day><month>2</month><year>2018</year></pub-date><pub-date pub-type="ppub"><month>5</month><year>2018</year></pub-date><volume>20</volume><issue>5</issue><issue-id pub-id-type="doi">10.1111/dom.2018.20.issue-5</issue-id><fpage>1306</fpage><lpage>1310</lpage><history><date date-type="received"><day>11</day><month>10</month><year>2017</year></date><date date-type="rev-recd"><day>28</day><month>12</month><year>2017</year></date><date date-type="accepted"><day>31</day><month>12</month><year>2017</year></date></history><permissions><copyright-statement content-type="article-copyright">© 2018 The Authors. <styled-content style="italic-in-any-context">Diabetes, Obesity and Metabolism</styled-content> published by John Wiley &amp; Sons Ltd.</copyright-statement><license license-type="creativeCommonsBy-nc-nd"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:DOM-20-1306.pdf"/><abstract><p><SecTag type="ABS"><text><SENT sid="1" pm="."><plain>The aim of the present study was to compare the effectiveness and safety of add‐on treatment with dapagliflozin to placebo in patients with prednisone‐induced hyperglycaemia during treatment for acute exacerbation of chronic obstructive pulmonary disease (AECOPD). </plain></SENT>
<SENT sid="2" pm="."><plain>We enrolled 46 patients hospitalized for an AECOPD in a multicentre double‐blind randomized controlled study in which add‐on treatment with dapagliflozin 10 mg was compared with placebo. </plain></SENT>
<SENT sid="3" pm="."><plain>Glycaemic control and incidence of hypoglycaemia were measured through a blinded subcutaneous continuous glucose monitoring device. </plain></SENT>
<SENT sid="4" pm="."><plain>Participants in the dapagliflozin group spent 54 ± 27.7% of the time in target range (3.9–10 mmol/L) and participants in the placebo group spent 53.6 ± 23.4% of the time in target range (P = .96). </plain></SENT>
<SENT sid="5" pm="."><plain>The mean glucose concentration was 10.1 mmol/L in the dapagliflozin group and 10.4 mmol/L in the placebo group (P = .66). </plain></SENT>
<SENT sid="6" pm="."><plain>One participant using dapagliflozin and 2 participants using placebo experienced symptomatic hypoglycaemia. </plain></SENT>
<SENT sid="7" pm="."><plain>Treatment with dapagliflozin was safe and there was no difference in risk of hypoglycaemia compared with placebo. </plain></SENT>
<SENT sid="8" pm="."><plain>Dapagliflozin did not result in better glycaemic control compared with placebo in participants with prednisone‐induced hyperglycaemia during AECOPD. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group kwd-group-type="author-generated"><kwd id="dom13209-kwd-0001">clinical trial</kwd><kwd id="dom13209-kwd-0002">continuous glucose monitoring (CGM)</kwd><kwd id="dom13209-kwd-0003">dapagliflozin</kwd><kwd id="dom13209-kwd-0004">glycaemic control</kwd><kwd id="dom13209-kwd-0005">hypoglycaemia</kwd><kwd id="dom13209-kwd-0006">randomized trial</kwd></kwd-group></SecTag><funding-group><award-group><funding-source>Investigator‐initiated project Astra Zeneca</funding-source></award-group></funding-group><counts><fig-count count="0"/><table-count count="2"/><page-count count="5"/><word-count count="3256"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>dom13206</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>May 2018</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.3.8.2 mode:remove_FC converted:11.05.2018</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="dom13209-cit-9001">
<string-name>
<surname>Gerards</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Venema</surname>
<given-names>GE</given-names>
</string-name>, <string-name>
<surname>Patberg</surname>
<given-names>KW</given-names>
</string-name>, et al. <article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Dapagliflozin for prednisone‐induced hyperglycaemia in acute exacerbation of chronic obstructive pulmonary disease </plain></SENT>
</text></SecTag></article-title>. <source xml:lang="en">Diabetes Obes Metab.</source>
<year>2018</year>;<volume>20</volume>:<fpage>1306</fpage>–<lpage>1310</lpage>. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/dom.13209">https://doi.org/10.1111/dom.13209</ext-link>
<pub-id pub-id-type="pmid">29316157</pub-id></mixed-citation>
</p><fn-group id="dom13209-ntgp-0101"><fn id="dom13209-note-0101"><p><text><SENT sid="1" pm="."><plain>Funding information Investigator‐initiated project Astra Zeneca </plain></SENT>
</text></p></fn></fn-group></notes></front><body><SecTag type="INTRO"><sec id="dom13209-sec-0001"><label>1</label><title><text><SENT sid="2" pm="."><plain>INTRODUCTION </plain></SENT>
</text></title><p><text><SENT sid="3" pm="."><plain>Hospitalization for acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is complicated by hyperglycaemia in 53% to 82% of patients without pre‐existing diabetes, and in 96% to 100% of patients with pre‐existing diabetes.1 Hyperglycaemia during AECOPD is associated with longer hospitalization and higher mortality rates.2 </plain></SENT>
</text></p><p><text><SENT sid="4" pm="."><plain>Patients with chronic obstructive pulmonary disease (COPD) frequently need systemic glucocorticoid therapy for AECOPD. </plain></SENT>
<SENT sid="5" pm="."><plain>Treatment with 30 to 40 mg prednisone for 5 to 14 days limits the duration and severity of an exacerbation.3 </plain></SENT>
</text></p><p><text><SENT sid="6" pm="."><plain>As a side effect, prednisone increases endogenous glucose production and induces insulin resistance.4 These phenomena result in a specific pattern of postprandial hyperglycaemia starting ~3 hours after administration and continuing for 24 to 36 hours.1 </plain></SENT>
</text></p><p><text><SENT sid="7" pm="."><plain>Treatment of hyperglycaemia attributable to prednisone can be challenging because of severe insulin resistance. </plain></SENT>
<SENT sid="8" pm="."><plain>Current practice is insulin therapy, often administered in a sliding‐scale regimen.5 However, high doses and frequent adjustments are required and, despite intensive treatment, glycaemic control is often inadequate.6 Furthermore, duration of hospital stay for AECOPD is usually shorter than duration of prednisone therapy, so patients often finish their prednisone course at home.3 Intensive insulin regimens may be difficult to execute outside the hospital, especially for insulin‐naïve patients. </plain></SENT>
</text></p><p><text><SENT sid="9" pm="."><plain>Sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors are oral agents that block renal glucose reabsorption, leading to urinary glucose excretion and thereby to a reduction in blood glucose concentration.7 Their mechanism of action is independent of β‐cell function and different from agents improving insulin sensitivity. </plain></SENT>
<SENT sid="10" pm="."><plain>SGLT2 inhibitors therefore have a complementary effect to routine diabetes medication in patients with pre‐existing diabetes.8 The low risk of hypoglycaemia and rapid onset of action (maximum plasma concentration achieved within 1–2 hours after oral administration) make SGLT2 inhibitors an attractive option for treatment of prednisone‐induced hyperglycaemia during AECOPD.9 </plain></SENT>
</text></p><p><text><SENT sid="11" pm="."><plain>The aim of the present study was to compare the effectiveness and safety of add‐on treatment with dapagliflozin 10 mg once daily with placebo in patients with prednisone‐induced hyperglycaemia during treatment for AECOPD. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec id="dom13209-sec-0002"><label>2</label><title><text><SENT sid="12" pm="."><plain>METHODS </plain></SENT>
</text></title><p><text><SENT sid="13" pm="."><plain>We enrolled patients hospitalized for AECOPD who were treated with at least 30 mg prednisone daily in a double‐blind randomized controlled study. </plain></SENT>
<SENT sid="14" pm="."><plain>Patients were eligible if they 1) had either a known history of type 2 diabetes or blood glucose &gt;10 mmol/L at admission; 2) had a prescription for systemic prednisone ≥30 mg for a period of 5 to 14 days; and 3) were aged ≥18 years and gave written informed consent. </plain></SENT>
<SENT sid="15" pm="."><plain>Exclusion criteria were: intensive care unit admission; estimated glomerular filtration rate &lt; 60 mL/min/1.73m2; recurrent genital infection; current use of any SGLT2‐inhibiting agent; volume depletion; congestive heart failure New York Heart Association class IV; cerebrovascular or cardiovascular event within 2 months before inclusion; suspected liver disease; and pregnancy or breastfeeding. </plain></SENT>
</text></p><p><text><SENT sid="16" pm="."><plain>Participants were randomly assigned to dapagliflozin or placebo as add‐on to their eventual routine diabetes medication. </plain></SENT>
<SENT sid="17" pm="."><plain>Randomization was carried out through a web‐based application.10 Routine glucose‐lowering medication and treatment for AECOPD were at the discretion of the treating physician. </plain></SENT>
</text></p><p><text><SENT sid="18" pm="."><plain>Participants continued study treatment until the end of the prednisone course, and also when participants continued prednisone treatment after hospital discharge. </plain></SENT>
<SENT sid="19" pm="."><plain>The maximum study duration was 14 days. </plain></SENT>
<SENT sid="20" pm="."><plain>Participants were counselled on the correct use of the glucose meter (OneTouch VerioIQ; LifeScan Inc., Chesterbrook, Pennsylvania) and on signs and symptoms of hypoglycaemia. </plain></SENT>
</text></p><p><text><SENT sid="21" pm="."><plain>Capillary glucose testing was done before each meal and at bedtime. </plain></SENT>
<SENT sid="22" pm="."><plain>During hospitalization, glucose values were also measured through a blinded subcutaneous continuous glucose monitoring (CGM) device (iPro2; Medtronic, Northridge, California). </plain></SENT>
<SENT sid="23" pm="."><plain>The occurrence of adverse events was evaluated during hospitalization and at end of study. </plain></SENT>
</text></p><p><text><SENT sid="24" pm="."><plain>The study was conducted in four secondary teaching hospitals in the Netherlands. </plain></SENT>
<SENT sid="25" pm="."><plain>The study protocol (<ext-link ext-link-type="uri" xlink:href="http://clinicaltrial.gov">http://clinicaltrial.gov</ext-link>: NCT02253121) was approved by the institutional review board. </plain></SENT>
</text></p><p><text><SENT sid="26" pm="."><plain>The primary outcomes were difference in glycaemic control, defined as the proportion of time spent in glucose target range (3.9–10 mmol/L), and difference in incidence of hypoglycaemia. </plain></SENT>
<SENT sid="27" pm="."><plain>Secondary outcomes were mean glucose concentration, need for initiation or adjustment of insulin treatment, patient satisfaction (Diabetes Treatment Satisfaction Questionnaire for Inpatients, DTSQ‐IP 11) and duration of hospitalization. </plain></SENT>
<SENT sid="28" pm="."><plain>Clinical hypoglycaemia was defined as symptoms consistent with hypoglycaemia together with a glucose value &lt;3.9 mmol/L, and subclinical hypoglycaemia was defined as the registration of a glucose value &lt;3.9 mmol/L (either by CGM or capillary glucose testing) without symptoms. </plain></SENT>
</text></p><p><text><SENT sid="29" pm="."><plain>We estimated the sample size based on glycaemic control in patients treated with dapagliflozin.12 We expected the proportion of time in target range to be 10 ± 10% higher in the dapagliflozin group compared with placebo. </plain></SENT>
<SENT sid="30" pm="."><plain>A total of 18 participants were needed in each group to achieve 80% power at P &lt; .05. </plain></SENT>
<SENT sid="31" pm="."><plain>To account for drop‐outs, we planned to include 46 participants. </plain></SENT>
<SENT sid="32" pm="."><plain>Regarding incidence of hypoglycaemia, non‐inferiority was established if the upper limit of the confidence interval (CI) of the difference was equal to or less than the non‐inferiority margin of 3%. </plain></SENT>
<SENT sid="33" pm="."><plain>With a sample size of 23 in each group, the study had 85% power to reject the hypothesis that the incidence of hypoglycaemia during dapagliflozin treatment was higher than during placebo treatment. </plain></SENT>
</text></p></sec></SecTag><SecTag type="RESULTS"><sec id="dom13209-sec-0003"><label>3</label><title><text><SENT sid="34" pm="."><plain>RESULTS </plain></SENT>
</text></title><p><text><SENT sid="35" pm="."><plain>Between March 2015 and February 2017, 46 participants were randomized (Figure S1). </plain></SENT>
<SENT sid="36" pm="."><plain>The mean duration of study medication was 7.3 (range 2–14) days in both groups. </plain></SENT>
<SENT sid="37" pm="."><plain>All randomized patients were included in the analysis. </plain></SENT>
</text></p><p><text><SENT sid="38" pm="."><plain>Eighty‐five percent of the patients already had type 2 diabetes before inclusion. </plain></SENT>
<SENT sid="39" pm="."><plain>Glycaemic control and routine diabetes medication at baseline were not different between treatment groups (Table 1). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="dom13209-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p><text><SENT sid="40" pm="."><plain>Baseline characteristics </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th colspan="2" align="left" valign="bottom" rowspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1"><text><SENT sid="41" pm="."><plain>Dapagliflozin (n = 23) </plain></SENT>
</text></th><th align="left" valign="bottom" rowspan="1" colspan="1"><text><SENT sid="42" pm="."><plain>Placebo (n = 23) </plain></SENT>
</text></th></tr></thead><tbody valign="top"><tr><td colspan="2" align="left" valign="top" rowspan="1"><text><SENT sid="43" pm="."><plain>Mean (SD) age, years </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="44" pm="."><plain>73.8 (8.7) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="45" pm="."><plain>70.7 (9.5) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="46" pm="."><plain>Sex, n (%) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="47" pm="."><plain>Women </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="48" pm="."><plain>9 (39.1) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="49" pm="."><plain>13 (56.5) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="50" pm="."><plain>Men </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="51" pm="."><plain>14 (60.9) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="52" pm="."><plain>10 (43.5) </plain></SENT>
</text></td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1"><text><SENT sid="53" pm="."><plain>Mean (SD) body mass index, kg/m2 </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="54" pm="."><plain>28.3 (5.4) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="55" pm="."><plain>28.9 (8) </plain></SENT>
</text></td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1"><text><SENT sid="56" pm="."><plain>Mean (SD) systolic/diastolic blood pressure, mm Hg </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="57" pm="."><plain>135 (17.9) / 75.4 (14) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="58" pm="."><plain>139 (19.8) / 79.9 (14.2) </plain></SENT>
</text></td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1"><text><SENT sid="59" pm="."><plain>Mean (SD) CRP, mg/L </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="60" pm="."><plain>62.4 (63.9) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="61" pm="."><plain>55.6 (63.1) </plain></SENT>
</text></td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1"><text><SENT sid="62" pm="."><plain>Mean (SD) leukocytes, 10E9/L </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="63" pm="."><plain>12 (4.5) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="64" pm="."><plain>12 (4.9) </plain></SENT>
</text></td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1"><text><SENT sid="65" pm="."><plain>Mean (SD) creatinine, μmol/L </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="66" pm="."><plain>77.8 (11.5) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="67" pm="."><plain>72.7 (16.4) </plain></SENT>
</text></td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1"><text><SENT sid="68" pm="."><plain>Mean (SD) glucose, mmol/L </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="69" pm="."><plain>11.4 (4.1) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="70" pm="."><plain>11.2 (4) </plain></SENT>
</text></td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1"><text><SENT sid="71" pm="."><plain>Mean (SD) HbA1c, % </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="72" pm="."><plain>7.0 (0.9) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="73" pm="."><plain>7.0 (1.0) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="74" pm="."><plain>COPD Gold stage, n (%) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="75" pm="."><plain>I–II </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="76" pm="."><plain>5 (21.7) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="77" pm="."><plain>10 (43.5) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="78" pm="."><plain>III–IV </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="79" pm="."><plain>16 (69.6) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="80" pm="."><plain>11 (47.8) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="81" pm="."><plain>Unknown </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="82" pm="."><plain>2 (8.7) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="83" pm="."><plain>2 (8.7) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="84" pm="."><plain>Diabetes, n (%) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="85" pm="."><plain>Type 2 diabetes </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="86" pm="."><plain>21 (91.3) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="87" pm="."><plain>18 (78.3) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="88" pm="."><plain>Diabetes duration, years </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="89" pm="."><plain>8.5 (5.2) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="90" pm="."><plain>8.5 (6.9) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="91" pm="."><plain>Treatment, n (%) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="92" pm="."><plain>Metformin </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="93" pm="."><plain>14/23 (60.9) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="94" pm="."><plain>14/23 (60.9) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="95" pm="."><plain>Mean (SD) daily dose, mg </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="96" pm="."><plain>1329 (363) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="97" pm="."><plain>1650 (754) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="98" pm="."><plain>Sulphonylureas </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="99" pm="."><plain>3 / 23 (13.0) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="100" pm="."><plain>8 / 23 (34.8) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="101" pm="."><plain>Metformin + sulphonylureas </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="102" pm="."><plain>3 / 23 (13.0) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="103" pm="."><plain>8 / 23 (34.8) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="104" pm="."><plain>Insulin </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="105" pm="."><plain>5 / 23 (21.7) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="106" pm="."><plain>5 / 23 (21.7) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="107" pm="."><plain>Daily insulin dose, IU </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="108" pm="."><plain>62.8 (20.4) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="109" pm="."><plain>52.0 (37.7) </plain></SENT>
</text></td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1"><text><SENT sid="110" pm="."><plain>Antibiotics started, n (%) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="111" pm="."><plain>17 (73.9) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="112" pm="."><plain>16 (69.6) </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn id="dom13209-note-0001"><p><text><SENT sid="113" pm="."><plain>Abbreviations: COPD, chronic obstructive pulmonary disease; CRP, C‐reactive protein; HbA1c, glycated haemoglobin. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="114" pm="."><plain>Glucose concentration was within target range (3.9–10 mmol/L) 54 ± 27.7% of the time in the dapagliflozin group and 53.6 ± 23.4% of the time in the placebo group (P = .96). </plain></SENT>
<SENT sid="115" pm="."><plain>Mean glucose was not different between dapagliflozin and placebo treatment groups (10.1 vs 10.4 mmol/L, mean difference 0.32 [95% CI –1.8 to 1.1]). </plain></SENT>
</text></p><p><text><SENT sid="116" pm="."><plain>Intensification of insulin treatment was observed in 12 participants (52.1%) in the dapagliflozin group and 14 (60.8%) in the placebo group (P = .55). </plain></SENT>
<SENT sid="117" pm="."><plain>There was a trend for a stronger increase in insulin dose in placebo compared with dapagliflozin treatment (mean difference 2.78 IU [95% CI –8.5 to 2.9]; Table 2). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="dom13209-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p><text><SENT sid="118" pm="."><plain>Glycaemic control and use of insulin during the study </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th colspan="2" align="left" valign="bottom" rowspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1"><text><SENT sid="119" pm="."><plain>Dapagliflozin (n = 23) </plain></SENT>
</text></th><th align="left" valign="bottom" rowspan="1" colspan="1"><text><SENT sid="120" pm="."><plain>Placebo (n = 23) </plain></SENT>
</text></th><th align="left" valign="bottom" rowspan="1" colspan="1"><text><SENT sid="121" pm="."><plain>Mean difference (95% CI) </plain></SENT>
</text></th><th align="center" valign="bottom" rowspan="1" colspan="1"><text><SENT sid="122" pm="."><plain>P </plain></SENT>
</text></th></tr></thead><tbody valign="top"><tr><td colspan="2" align="left" valign="top" rowspan="1"><text><SENT sid="123" pm="."><plain>Mean (SD) % of time in target range (3.9–10 mmol/L) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="124" pm="."><plain>54 (27.7) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="125" pm="."><plain>53.6 (23.4) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="126" pm="."><plain>0.4 (−14.9; 15.7) </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="127" pm="."><plain>0.96 </plain></SENT>
</text></td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1"><text><SENT sid="128" pm="."><plain>Mean (SD) % of time &gt; 10 mmol/L </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="129" pm="."><plain>45.5 (28.1) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="130" pm="."><plain>45.9 (23.5) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="131" pm="."><plain>−0.33 (−15.7; 15) </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="132" pm="."><plain>0.97 </plain></SENT>
</text></td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1"><text><SENT sid="133" pm="."><plain>Mean (SD) % of time &gt; 15 mmol/L </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="134" pm="."><plain>10.6 (13) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="135" pm="."><plain>15.1 (17) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="136" pm="."><plain>−4.53 (−13.5; 4.5) </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="137" pm="."><plain>0.32 </plain></SENT>
</text></td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1"><text><SENT sid="138" pm="."><plain>Mean (SD) % of time &gt; 20 mmol/L </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="139" pm="."><plain>1.5 (5.3) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="140" pm="."><plain>2.8 (5.4) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="141" pm="."><plain>−1.33 (−4.5; 1.8) </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="142" pm="."><plain>0.40 </plain></SENT>
</text></td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1"><text><SENT sid="143" pm="."><plain>Mean (SD) glucose value </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="144" pm="."><plain>10.1 (2.4) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="145" pm="."><plain>10.4 (2.5) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="146" pm="."><plain>−0.32 (−1.8; 1.1) </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="147" pm="."><plain>0.66 </plain></SENT>
</text></td></tr><tr><td rowspan="4" align="left" valign="top" colspan="1"><text><SENT sid="148" pm="."><plain>Insulin use during study, n (%) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="149" pm="."><plain>No change </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="150" pm="."><plain>11 (47.8) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="151" pm="."><plain>9 (39.1) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="152" pm="."><plain>χ2 0.45 </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="153" pm="."><plain>0.80 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="154" pm="."><plain>Insulin started </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="155" pm="."><plain>7 (30.4) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="156" pm="."><plain>9 (39.1) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="157" pm="."><plain>Dose increase </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="158" pm="."><plain>5 (21.7) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="159" pm="."><plain>5 (21.7) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="160" pm="."><plain>Dose decrease </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="161" pm="."><plain>0 (0) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="162" pm="."><plain>0 (0) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td colspan="2" align="left" valign="top" rowspan="1"><text><SENT sid="163" pm="."><plain>Mean (SD) daily insulin dose during study (units per day) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="164" pm="."><plain>18.3 (32.4) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="165" pm="."><plain>19.3 (34) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="166" pm="."><plain>−0.95 (−20.9; 19) </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="167" pm="."><plain>0.92 </plain></SENT>
</text></td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1"><text><SENT sid="168" pm="."><plain>Mean (SD) absolute change in insulin dose from baseline </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="169" pm="."><plain>4.7 (7.5) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="170" pm="."><plain>7.4 (11.1) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="171" pm="."><plain>−2.78 (−8.5; 2.9) </plain></SENT>
</text></td><td align="center" valign="top" rowspan="1" colspan="1"><text><SENT sid="172" pm="."><plain>0.33 </plain></SENT>
</text></td></tr></tbody></table></table-wrap></SecTag><p><text><SENT sid="173" pm="."><plain>There was no difference in duration of hospital stay (dapagliflozin vs placebo 8.2 ± 4.2 vs 8.1 ± 5.4 days; P = 0.95). </plain></SENT>
<SENT sid="174" pm="."><plain>Patients treated with dapagliflozin had a mean weight loss of 0.54 kg during study treatment, whereas patients treated with placebo gained 0.75 kg (mean difference −1.28 kg [95% CI –3.07 to 0.49]). </plain></SENT>
<SENT sid="175" pm="."><plain>The composite satisfaction score in the dapagliflozin group was 97.1 ± 13.2 out of a maximum of 120 vs 94.8 ± 14.3 in the placebo group (mean difference 2.34 [95% CI –6.5 to 11.2]). </plain></SENT>
</text></p><p><text><SENT sid="176" pm="."><plain>In total, there were 18 hypoglycaemic events: 8 events in 5 participants treated with dapagliflozin and 10 events in 6 participants on placebo. </plain></SENT>
<SENT sid="177" pm="."><plain>In the dapagliflozin group, 1 participant experienced symptomatic hypoglycaemia, and in the placebo group, 2 participants experienced symptomatic hypoglycaemia. </plain></SENT>
<SENT sid="178" pm="."><plain>The other 8 participants had subclinical hypoglycaemic events recorded by CGM or capillary glucose testing only. </plain></SENT>
<SENT sid="179" pm="."><plain>We observed no severe hypoglycaemic events. </plain></SENT>
</text></p><p><text><SENT sid="180" pm="."><plain>A total of 19 non‐hypoglycaemic adverse events occurred in the dapagliflozin group vs 12 in the placebo group (Table S1). </plain></SENT>
<SENT sid="181" pm="."><plain>There was no statistically significant difference in the incidence of hypoglycaemic and non‐hypoglycaemic adverse events between the dapagliflozin and the placebo group. </plain></SENT>
</text></p></sec></SecTag><SecTag type="DISCUSS"><sec id="dom13209-sec-0004"><label>4</label><title><text><SENT sid="182" pm="."><plain>DISCUSSION </plain></SENT>
</text></title><p><text><SENT sid="183" pm="."><plain>In this randomized controlled study in patients with AECOPD, we compared the effectiveness of add‐on treatment with dapagliflozin to placebo for prednisone‐induced hyperglycaemia. </plain></SENT>
<SENT sid="184" pm="."><plain>Although treatment with dapagliflozin appeared to be safe, dapagliflozin did not result in better glycaemic control compared with placebo. </plain></SENT>
<SENT sid="185" pm="."><plain>This is the first study to date that assessed the effectiveness of an SGLT2‐inhibiting agent in prednisone‐induced hyperglycaemia. </plain></SENT>
</text></p><p><text><SENT sid="186" pm="."><plain>Participants treated with dapagliflozin had glucose values similar to those treated with placebo. </plain></SENT>
<SENT sid="187" pm="."><plain>The slight benefit in participants treated with dapagliflozin was neither statistically significant nor clinically relevant. </plain></SENT>
<SENT sid="188" pm="."><plain>Participants were exposed to at least 30 mg systemic prednisone daily and had severe hyperglycaemia, with glucose values &gt;15 mmol/L for 11% to 15% of the time. </plain></SENT>
<SENT sid="189" pm="."><plain>The glucose‐lowering effect of dapagliflozin was probably too weak to reach target ranges &lt;10 mmol/L in these participants.9 </plain></SENT>
</text></p><p><text><SENT sid="190" pm="."><plain>Our study participants consisted of patients with AECOPD requiring hospitalization, and the majority had a concomitant pulmonary infection. </plain></SENT>
<SENT sid="191" pm="."><plain>Many of the patients had severe hyperglycaemia and needed treatment intensification. </plain></SENT>
<SENT sid="192" pm="."><plain>We cannot draw conclusions from the present study about the use of SGLT2‐inhibiting agents in other populations using glucocorticoid agents. </plain></SENT>
<SENT sid="193" pm="."><plain>Hypothetically, dapagliflozin may benefit patients with milder levels of hyperglycaemia attributable to lower‐dose chronic glucocorticoid treatment, such as after organ transplantation or in rheumatoid arthritis. </plain></SENT>
<SENT sid="194" pm="."><plain>For these patients, who are often treated on an outpatient basis, an oral once‐daily agent that possibly reduces the incidence of insulin initiation would be valuable. </plain></SENT>
</text></p><p><text><SENT sid="195" pm="."><plain>During follow‐up, insulin therapy was initiated in 16 out of 36 insulin‐naïve patients, which emphasizes the clinical relevance of prednisone‐induced hyperglycaemia in patients with AECOPD. </plain></SENT>
<SENT sid="196" pm="."><plain>Although the present study was not powered to detect subtle changes in insulin therapy, we observed a trend for lower incidence of insulin initiation in patients treated with dapagliflozin and lower increase of insulin dose in patients who already used insulin at baseline. </plain></SENT>
</text></p><p><text><SENT sid="197" pm="."><plain>Strengths of the present study include the double‐blind placebo‐controlled study design that was executed in 4 hospitals, and the thorough outcome measurement through CGM. </plain></SENT>
<SENT sid="198" pm="."><plain>Also, we estimated the required sample size to be able to detect differences in glycaemic control as well as with regard to safety. </plain></SENT>
<SENT sid="199" pm="."><plain>However, an average study duration of 7.4 days limited the power to find a difference in incidence of hypoglycaemic events and, possibly to a lesser extent, to find a difference in glycaemic control. </plain></SENT>
<SENT sid="200" pm="."><plain>Another limitation of the study is related to the add‐on treatment design, in which treating physicians were free to adjust glucose‐lowering treatment. </plain></SENT>
<SENT sid="201" pm="."><plain>This strategy, although a reflection of real‐life practice, could have masked differences in glycaemic control between patients treated with dapagliflozin and placebo. </plain></SENT>
</text></p><p><text><SENT sid="202" pm="."><plain>Despite our negative results, we are convinced that the present study is valuable given the scarcity of evidence on treatment of glucocorticoid‐induced hyperglycaemia. </plain></SENT>
<SENT sid="203" pm="."><plain>Glucagon‐like peptide‐1‐mediating agents have been suggested to be beneficial in preclinical studies but have not yet been studied in a clinical setting.13, 14 Thiazolidinediones were suggested to be effective in chronic glucocorticoid‐induced hyperglycaemia in a pilot study, but the findings were never confirmed in a comparative study. </plain></SENT>
<SENT sid="204" pm="."><plain>Moreover, thiazolidinediones carry risks of heart failure and liver toxicity.15, 16 Metformin was shown to counter dexamethasone‐induced hyperglycaemia in mice, but was not studied systematically in humans.17 Intensive insulin regimens are currently the treatment of choice but have a high burden (frequent monitoring, dose adjustment, risk of hypoglycaemia) and often do not result in sufficient glycaemic control. </plain></SENT>
<SENT sid="205" pm="."><plain>Future studies are therefore needed on the effect of SGLT2‐inhibiting agents and on treatment strategies with other agents in patients with acute and chronic glucocorticoid‐induced hyperglycaemia. </plain></SENT>
</text></p><p><text><SENT sid="206" pm="."><plain>In conclusion, dapagliflozin did not improve glycaemic control in patients with prednisone‐induced hyperglycaemia during AECOPD. </plain></SENT>
<SENT sid="207" pm="."><plain>In future studies, it would be interesting to study its effect in patients with less severe hyperglycaemia caused by lower‐dose chronic glucocorticoid treatment. </plain></SENT>
</text></p></sec></SecTag><SecTag type="SUPPL"><sec sec-type="supplementary-material"><title><text><SENT sid="208" pm="."><plain>Supporting information </plain></SENT>
</text></title><supplementary-material content-type="local-data" id="dom13209-supitem-0001"><caption><p><text><SENT sid="209" pm="."><plain>Figure S1. Patient flow diagram </plain></SENT>
</text></p><p><text><SENT sid="210" pm="."><plain>Table S1. Adverse events </plain></SENT>
</text></p></caption><media xlink:href="DOM-20-1306-s001.docx"><caption><p><text><SENT sid="211" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack id="dom13209-sec-0005"><title>ACKNOWLEDGMENTS</title><p><text4fund><text><SENT sid="212" pm="."><plain>AstraZeneca supplied the dapagliflozin, placebo and funding for this investigator‐initiated project. </plain></SENT>
<SENT sid="213" pm="."><plain>We thank Thomas Boerlage, Paula Wolvers, Floris Westerink, Lucie Kappelle, Stefan Walen and Bob van den Berg for helping with recruitment of patients. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="REF"><ref-list id="dom13209-bibl-0001" content-type="cited-references"><title>REFERENCES</title><ref id="dom13209-bib-0001"><text><SENT sid="214" pm="."><plain>1  Burt MG ,  Roberts GW ,  Aguilar‐Loza NR ,  Frith P ,  Stranks SN . Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD. J Clin Endocrinol Metab. 2011;96(6):1789‐1796.21411550 </plain></SENT>
</text></ref><ref id="dom13209-bib-0002"><text><SENT sid="215" pm="."><plain>2  Koskela HO ,  Salonen PH ,  Romppanen J ,  Niskanen L . A history of diabetes but not hyperglycaemia during exacerbation of obstructive lung disease has impact on long‐term mortality: a prospective, observational cohort study. BMJ Open. 2015;5(1):e006794. </plain></SENT>
</text></ref><ref id="dom13209-bib-0003"><text><SENT sid="216" pm="."><plain>3Celli BR, MacNee W,  ATS/ERS Task Force A , et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932‐946.15219010 </plain></SENT>
</text></ref><ref id="dom13209-bib-0004"><text><SENT sid="217" pm="."><plain>4  van Raalte DH ,  Ouwens DM ,  Diamant M . Novel insights into glucocorticoid‐mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest. 2009;39(2):81‐93.19200161 </plain></SENT>
</text></ref><ref id="dom13209-bib-0005"><text><SENT sid="218" pm="."><plain>5  Gerards MC ,  Cohen Tervaert E ,  Hoekstra JBL ,  Vriesendorp TM ,  Gerdes VEA . Physician's attitudes towards diagnosing and treating glucocorticoid induced hyperglycaemia: sliding scale regimen is still widely used despite guidelines. Diabetes Res Clin Pract. 2015;109(2):246‐252.26055758 </plain></SENT>
</text></ref><ref id="dom13209-bib-0006"><text><SENT sid="219" pm="."><plain>6  Gerards MC ,  de Maar JS ,  Steenbruggen TG ,  Hoekstra JBLJ ,  Vriesendorp TM ,  Gerdes VEA . Add‐on treatment with intermediate‐acting insulin versus sliding scale insulin for patients with type 2 diabetes or insulin resistance during cyclic glucocorticoid‐containing antineoplastic chemotherapy ‐ a randomized cross‐over study. Diabetes Obes Metab. 2016;18(10):1041‐1044.27191794 </plain></SENT>
</text></ref><ref id="dom13209-bib-0007"><text><SENT sid="220" pm="."><plain>7  Monami M ,  Nardini C ,  Mannucci E . Efficacy and safety of sodium glucose co‐transport‐2 inhibitors in type 2 diabetes: a meta‐analysis of randomized clinical trials. Diabetes Obes Metab. 2014;16(5):457‐466.24320621 </plain></SENT>
</text></ref><ref id="dom13209-bib-0008"><text><SENT sid="221" pm="."><plain>8  Clar C ,  Gill JA ,  Court R ,  Waugh N . Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open. 2012;2(5):e001007. </plain></SENT>
</text></ref><ref id="dom13209-bib-0009"><text><SENT sid="222" pm="."><plain>9  Plosker GL . Dapagliflozin: a review of its use in type 2 diabetes mellitus. Drugs. 2012;72(17):2289‐2312.23170914 </plain></SENT>
</text></ref><ref id="dom13209-bib-0010"><text><SENT sid="223" pm="."><plain>10 ALEA Online randomisation software. </plain></SENT>
<SENT sid="224" pm="."><plain>Abcoude, The Netherlands: ALEA Clinical FormsVision; 2004. </plain></SENT>
</text></ref><ref id="dom13209-bib-0011"><text><SENT sid="225" pm="."><plain>11  Sampson MJ ,  Singh H ,  Dhatariya KK ,  Jones C ,  Walden E ,  Bradley C . Psychometric validation and use of a novel diabetes in‐patient treatment satisfaction questionnaire. Diabet Med. 2009;26(7):729‐735.19573123 </plain></SENT>
</text></ref><ref id="dom13209-bib-0012"><text><SENT sid="226" pm="."><plain>12  Komoroski B ,  Vachharajani N ,  Feng Y ,  Li L ,  Kornhauser D ,  Pfister M . Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2009;85(5):513‐519.19129749 </plain></SENT>
</text></ref><ref id="dom13209-bib-0013"><text><SENT sid="227" pm="."><plain>13  van Raalte DH ,  van Genugten R ,  Linssen M ,  Ouwens D ,  Diamant M . Glucagon‐like Peptide‐1 Receptor Agonist Treatment Prevents Glucocorticoid‐Induced Glucose Intolerance and Islet‐Cell Dysfunction in Humans. Diabetes Care. 2011;34:412‐417.21216851 </plain></SENT>
</text></ref><ref id="dom13209-bib-0014"><text><SENT sid="228" pm="?"><plain>14  van Genugten RE ,  van Raalte DH ,  Muskiet MH , et al. Does dipeptidyl peptidase‐4 inhibition prevent the diabetogenic effects of glucocorticoids in men with the metabolic syndrome? </plain></SENT>
<SENT sid="229" pm="."><plain>A randomized controlled trial. Eur J Endocrinol. 2014;170(3):429‐439.24297090 </plain></SENT>
</text></ref><ref id="dom13209-bib-0015"><text><SENT sid="230" pm="."><plain>15  Morita H ,  Oki Y ,  Ito T ,  Ohishi H ,  Suzuki S ,  Nakamura H . Administration of Troglitazone, but Not Pioglitazone, Reduces Insulin Resistance Caused by Short‐Term Dexamethasone (DXM) Treatment by Accelerating the Metabolism of DXM. Diabetes Care. 2001;24(4):788‐789.11315852 </plain></SENT>
</text></ref><ref id="dom13209-bib-0016"><text><SENT sid="231" pm="."><plain>16  Lago RM ,  Singh PP ,  Nesto RW . Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta‐analysis of randomised clinical trials. Lancet. 2007;370(9593):1129‐1136.17905165 </plain></SENT>
</text></ref><ref id="dom13209-bib-0017"><text><SENT sid="232" pm="."><plain>17  Thomas CR ,  Turner SL ,  Jefferson WH ,  Bailey CJ . Prevention of dexamethasone‐induced insulin resistance by metformin. Biochem Pharmacol. 1998;56(9):1145‐1150.9802324 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
